FindTrial
Sign In

Study on the real world of barnidipine hydrochloride sustained - release capsule

A observation of barnidipine hydrochloride sustaine -release Capsules ( Fanqi ) to the effect of blood pressure in hypertensive patients: prospective, single arm, non-interventive real world study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042410
Enrollment
Unknown
Registered
2021-01-21
Start date
2021-01-19
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Case series:Fanqi

Sponsors

Cangzhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria: aged >= 18 years, not limited to gender; 2. Subjects with hypertension diagnosed by experienced doctors should be treated symptomatically with Fanqi; 3. The subjects who understood the study agreed to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Subjects who had taken Fanqi within three months for various reasons; 2. Patients who are allergic to the product or judged by the researcher not suitable for the study; 3. Patients who participated in non intervention clinical research at the same time.

Design outcomes

Primary

MeasureTime frame
blood pressure;—

Countries

China

Contacts

Public ContactShutong Du

Cangzhou People's Hospital

hbcz19710215@sina.com+86 13582727570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026